The gross sales of remdesivir throughout the state have declined to 1,680 vials in to date in October as towards the file sale of 3.49 lakh injections in April. The antiviral drug’s month-to-month gross sales skyrocketed above 1 lakh vials throughout March to May, when the fierce second wave of the pandemic gripped the state and your entire nation. The remdesivir gross sales in October are the bottom after June 2020, exhibits information compiled by the Gujarat Food and Drug Control Administration.
Meanwhile, the oral antiviral drug favipiravir’s gross sales too have touched their lowest ranges for the reason that outbreak of the pandemic. About 408 tablets of favipiravir 200mg have been offered to date in October as towards the file gross sales of 34.47 lakh tablets in April this yr. The gross sales of favipiravir in 400mg and 800mg dosages have additionally nosedived to 780 tablets and 612 tablets, respectively, in October. In April, the 400 mg capsules’ gross sales had galloped to 1 crore tablets and 800 mg capsules to 14.45 lakh tablets, the state FDCA information additional confirmed.
“The sales of remdesivir and favipiravir have dropped to negligible levels, which is inline with the sharp reduction in cases of Covid-19 across the state,” mentioned Dr HG Koshia, commissioner, FDCA-Gujarat.
The gross sales of Covid drugs have been steadily lowering since June 2021, in keeping with state FDCA compiled information. “With more vaccination, cases have surely gone down. People are now more confident after vaccination and therefore, consumption of immunity boosters has reduced. As long as people wear masks in public places, things may remain under control,” mentioned Dr Bharat Gadhvi, president, Ahmedabad Hospitals’ & Nursing houses’ Association (AHNA).
“The sale of preventive and immunity-boosting medicines has completely taken a back seat. While mask sales continue, demand for sanitizers has drastically dropped too. People are getting complacent with the situation and therefore, spending on Covid-related medicines has reduced drastically. This trend has been observed since July this year,” mentioned Ankur Aggarwal, founder, MedKart.
, 2021-10-23 04:27:00